Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The allergen extracts in Oralair are absorbed through the oral mucosa, where they stimulate regulatory immune pathways. This leads to a gradual shift from IgE‑driven allergy responses toward IgG4 production and increased regulatory T‑cell activity, fostering long‑term tolerance to grass pollen.

The dosing regimen for Oralair is individualized. A qualified healthcare professional determines the starting dose, escalation schedule and maintenance dose based on the patient’s age, sensitivity profile and clinical response.

Safety data for Oralair in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their prescribing physician before starting treatment.

To request Oralair, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oralair is a sublingual tablet, offering a needle‑free alternative to injectable grass‑pollen extracts. It provides comparable efficacy in symptom reduction while allowing self‑administration at home, which can improve patient convenience and adherence compared with traditional subcutaneous immunotherapy.

Oralair tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity.

The tablet is placed under the tongue and allowed to dissolve completely without swallowing or drinking for a few minutes. Patients should remain seated and avoid eating or drinking for at least 10 minutes after administration, following the prescriber’s instructions.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe swelling of the tongue or throat, and persistent wheezing. Patients should be educated to recognize early signs of a severe reaction and seek immediate medical attention if they occur.

Oralair is contraindicated in individuals with a history of severe systemic reactions to grass‑pollen extracts, uncontrolled asthma, or those receiving beta‑blocker therapy without medical supervision. It should also be avoided in patients with active oral infections or severe dental disease.